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Abstract
Background: Progressive supranuclear palsy (PSP) with a frontal presentation, characterized by cognitive deficits
and behavioral changes, has been recognized as an early clinical picture, distinct from the classical so-called
Richardson and parkinsonism presentations. The midcingulate cortex is associated with executive and attention
tasks and has consistently been found to be impaired in imaging studies of patients with PSP. The aim of the
present study was to determine alterations in neurotransmission underlying the pathophysiology of PSP, as well as
their significance for clinically identifiable PSP subgroups.
Methods: In vitro receptor autoradiography was used to quantify densities of 20 different receptors in the caudate
nucleus and midcingulate area 24' of patients with PSP (n = 16) and age- and sex-matched control subjects (n = 14).
Results: Densities of γ-aminobutyric acid type B, peripheral benzodiazepine, serotonin receptor type 2, and N-
methyl-D-aspartate receptors were significantly higher in area 24′ of patients with PSP, where tau impairment was
stronger than in the caudate nucleus. Kainate and nicotinic cholinergic receptor densities were significantly lower,
and adenosine receptor type 1 (A1) receptors significantly higher, in the caudate nucleus of patients with PSP.
Receptor fingerprints also segregated PSP subgroups when clinical parameters such as occurrence of frontal
presentation and tau pathology severity were taken into consideration.
Conclusions: We demonstrate, for the first time to our knowledge, that kainate and A1 receptors are altered in PSP
and that clinically identifiable PSP subgroups differ at the neurochemical level. Numerous receptors were altered in
the midcingulate cortex, further suggesting that it may prove to be a key region in PSP. Finally, we add to the
evidence that nondopaminergic systems play a role in the pathophysiology of PSP, thus highlighting potential
novel treatment strategies.
Keywords: Progressive supranuclear palsy, Frontal presentation, Neurotransmitter receptors, Midcingulate cortex,
Caudate nucleus
Background
Progressive supranuclear palsy (PSP) is a neurodegenera-
tive disorder clinically characterized by early postural
instability, supranuclear gaze palsy, parkinsonism, and
cognitive decline [1]. Frontal presentation characterized
by cognitive deficits and behavioral changes has recently
been recognized as an early clinical picture [2, 3], distinct
from the classical so-called Richardson and parkinsonism
presentations [4]. Accordingly, the focus of research in
PSP has expanded over the years from neuropathological
studies of subcortical structures to investigations of the
disease as a more diffuse condition with varying cortical
involvement [5].
The midcingulate cortex, comprising areas 24′ and 32′
[6], is associated with executive and attention tasks [7] and
has consistently been found to be impaired in patients with
PSP [3]. A recent perfusion single-photon emission com-
puted tomography study confirmed and extended these
findings; the degree of midcingulate cortical hypoperfusion
correlated with the extent of executive dysfunction in
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patients [8], the cardinal feature of cognitive dysfunction in
PSP [9]. Therefore, understanding the neurochemical
changes in this region may prove crucial to finding a treat-
ment for cognitive symptoms.
Previous neurotransmitter studies in PSP have been fo-
cused mainly on nigrostriatal dopaminergic and choliner-
gic systems. Authors of a comprehensive review of in vivo
imaging studies addressing PSP-associated alterations of
synaptic transmission revealed that most existing studies
showed decreased dopamine transporter and dopamine
receptor type 2 (D2) binding densities in the striatum,
whereas dopamine receptor type 1 (D1) densities were
demonstrated to be unaltered [10]. In studies focused on
the cholinergic system, researchers reported significant
reductions of muscarinic and nicotinic receptors in the
striatum [11, 12]. Despite these findings, dopamine and
cholinergic replacement therapies in PSP have not proven
to be effective [13]. Therefore, other neurotransmitter sys-
tems may be involved.
An intriguing question is whether the midcingulate hypo-
metabolism found in PSP is accompanied by alterations in
the densities of specific neurotransmitter receptors. There-
fore, we applied quantitative in vitro receptor autoradiog-
raphy on unfixed brain tissue from patients with PSP and
control subjects to quantify the densities of 20 different re-
ceptor binding sites and determine PSP-related alterations
in the “receptor fingerprints” [14] of midcingulate area 24′.
Furthermore, because the midcingulate cortex and caudate
nucleus differ considerably in their neurochemical compos-
ition in the healthy brain [6, 14], and because different brain
regions are not necessarily affected in the same way by
disease [15], we also examined caudate nucleus tissue
obtained from the same patients with PSP.
Methods
Subjects
Brains were obtained from patients with PSP (aged 72 ±
7 years, 9 male, 7 female) recruited in a nationwide
study on PSP between 2000 and 2009. Brain autopsy was
conducted by The Netherlands Brain Bank according to
its Legal and Ethical Code of Conduct. Control subjects
consisted of age- and sex-matched subjects (aged 76 ±
10 years old, 9 male, 5 female) without a history of
neurological or psychiatric diseases.
Patients were examined after referral to the outpatient
department of the Erasmus University Medical Center and
by visiting patients in nursing homes as part of a large
longitudinal study [2, 16] approved by the medical ethics
committee of the Erasmus University Medical Center. All
participants or their first-degree relatives signed informed
consent forms. All patients were examined by a research
physician (W.Z.C. or L.D.K.) or a neurologist (A.J.W.B. or
J.C.v.S.). A detailed clinical history was obtained from pa-
tients and their family members and by reviewing medical
records. The neurological examination was videotaped ac-
cording to a standardized protocol. Structural neuroimag-
ing of patients was reviewed to exclude other disease
causes. Family history was considered positive when at least
one first-degree relative had dementia or parkinsonism.
The possibility of postmortem examination was discussed
with patients and their relatives. Relevant medication used
in the last 3 months of life was recorded. Clinical diagnosis
of patients was established in a consensus meeting accord-
ing to the National Institute of Neurological Diseases and
Stroke/Society for Progressive Supranuclear Palsy criteria
[1]. Neuropathological diagnosis of PSP was established ac-
cording to international criteria [17].
Standard neuropathology
At The Netherlands Brain Bank, the right hemispheres of
all brains are processed for routine staining and immuno-
histochemistry against several antibodies: AT8 (1:40;
Innogenetics, Ghent, Belgium), ubiquitin (1:500; Dako,
Glostrup, Denmark), three-repeat tau isoform (1:3000; Up-
state Biotechnology, Charlottesville, VA, USA), four-repeat
tau isoform (1:100; Upstate Biotechnology), p62 (1:200, fol-
lowing 80 °C antigen retrieval; BD Biosciences Pharmingen,
San Diego, CA, USA), trans-activation response DNA-
binding protein 43 (TDP-43, 1:100 following pressure-
cooking; Proteintech, Chicago, IL, USA), β-amyloid (anti-β-
amyloid, 1:100 following formic acid pretreatment; Dako),
and α-synuclein (anti-α-synuclein, undiluted following for-
mic acid pretreatment; Zymed Laboratories, South San
Francisco, CA, USA). Slides were incubated overnight at 4 °
C. Endogenous peroxidase activity was inhibited by 30-
minute incubation in a PBS-hydrogen peroxide-sodium
azide solution (100 ml of 0.1 M PBS, 2 ml of 30% H2O2,
1 ml of NaN3). The Histostain-Plus broad-spectrum immu-
nohistochemistry kit with 3,3′-diaminobenzidine (Zymed
Laboratories) was used as a detection system. Slides were
counterstained with Mayer’s hematoxylin and mounted in
Entellan medium (EMD Millipore, Billerica, MA, USA).
A separate semiquantitative assessment of tau pathology
for area 24′ and the caudate nucleus was carried out by
two raters (W.Z.C. and J.C.v.S.) using a 2-point grading
scale, which is an adaptation of the visual guide proposed
by Williams et al. [18]. We defined Williams’s grades 1
and 2 as mild and grades 3 and 4 as moderate to severe.
In vitro receptor autoradiography
Probes from midcingulate area 24′ and the caudate puta-
men were taken from the left hemisphere, frozen in isopen-
tane at −40 °C with a postmortem delay of 6 ± 1 h (patients
with PSP) and 8 ± 1 h (control subjects), and serially
sectioned at −20 °C in 10-μm-thick sections with a cryostat.
Alternating sections were processed for the visualization of
20 transmitter receptors according to standard protocols
(Table 1) comprising a preincubation to remove endogenous
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ligands and external substances such as medication, a main
incubation to label binding sites with a tritiated ligand in the
presence (nonspecific binding) or absence (total binding) of
a nonlabeled displacer, and a rinsing step to eliminate un-
bound radioactivity [14, 19]. Nonspecific binding was less
than 5% of total binding for all examined binding sites and
thus was ignored in the present study. All sections intended
for the visualization of a given receptor type were incubated
in the same radioactive solution.
Radioactively labeled sections were coexposed against
tritium-sensitive films (Amersham Hyperfilm®; GE Health-
care Life Sciences, Braunschweig, Germany) with plastic
[3H]-standards of known concentrations of radioactivity
(Amersham Microscales®; GE Healthcare Life Sciences).
Upon purchase, Microscales® were calibrated with the aid
of brain homogenate standards for which total protein con-
tent had been determined by means of the Bradford assay
[20]. Resulting autoradiographs were processed by densi-
tometry with a video-based image-analyzing technique [19].
The Microscales® were used to compute a calibration curve,
which, together with the parameters specific for each bind-
ing experiment (i.e., specific activity, dissociation constant,
and concentration of the ligand), enabled transformation of
grayscale values in the autoradiographs of samples into a
binding site density per unit of protein (femtomoles per
milligram of protein). Mean densities were thus obtained
for a series of three or four sections per receptor type in
the area 24′ and caudate nucleus probe of each case.
Statistical analysis
IBM SPSS Statistics version 21.0 for Windows software
(IBM, Armonk, NY, USA) was used for analysis. Demo-
graphic features were analyzed by independent samples t
test or chi-square test. Discriminant analyses were per-
formed separately for data from area 24′ and the caudate
nucleus to visualize the multivariate distance between con-
trol subjects and patients with PSP and between the two
groups into which the patients could be subdivided on the
basis of tau pathology severity or frontal versus nonfrontal
presentation. Only in the case of a significant result did we
perform post hoc tests (univariate F-tests) to reveal which
receptor types differed between control subjects and
patients with PSP or PSP subgroups. These p values were
not corrected for multiple comparisons. Significance levels
were set at p < 0.05 for the omnibus tests and p < 0.01 for
the post hoc tests. The discriminant analysis was chosen as
a global test because it offers several advantages over the
procedures classically used to test group differences [21], the
most important of which are that it is nonparametric and
that it supports the analysis of multivariate datasets with
more dependent variables (receptor densities, comprising 20
in this study) than cases (individuals in this study, compris-
ing 14 control subjects and 16 patients with PSP). This is ac-
complished by reducing the receptor densities to a smaller
number of discriminant scores (two in this study) for statis-
tical testing and graphing.
Results
No cases of PSP-parkinsonism were identified in the
present cohort, and relevant clinical data are summarized
in Tables 2 and 3.
Progressive supranuclear palsy cohort vs control subjects
On the basis of discriminant analyses of receptor
densities, classification of patients with PSP and control
subjects was significant in the caudate nucleus (Wilks’
lambda = 0.103, chi-square = 34.127, p = 0.025) and in
area 24′ (Wilks’ lambda = 0.071, chi-square = 47.592, p <
0.001). Post hoc univariate F-tests revealed significantly
higher densities of peripheral benzodiazepine (pBZ) and
adenosine receptor type 1 (A1) receptors, but lower
densities of kainate receptors and of nicotinic choliner-
gic receptors of the α4/β2 type (nACh) in the caudate
nucleus of PSP brains than in brains of control subjects
(Table 4, Fig 1a). In contrast to this, significantly higher
N-methyl-D-aspartate (NMDA), γ-aminobutyric acid re-
ceptor type B (GABAB), pBZ, and serotonin receptor
type 2 (5-HT2) receptor densities were found in area 24′
of PSP patient brains than in control brains (Table 5,
Fig. 1d).
Because patients with PSP displayed high interindividual
variability in receptor density alterations (see large SD in
Fig. 1a and d), we subdivided the cohort on the basis of
the clinical parameters presence of frontal presentation
and severity of tau pathology in the examined regions, and
we tested separately for data obtained from the caudate
nucleus and area 24′ whether these factors were associ-
ated with receptor density alterations in patients with PSP.
Progressive supranuclear palsy subgroups
Frontal presentation versus nonfrontal presentation
Discriminant analyses of receptor densities when the PSP
cohort was divided into cases with frontal (n = 7) and cases
with nonfrontal (n = 9) presentation resulted in a significant
segregation of these two clinically relevant pictures in both
the caudate nucleus (Wilks’ lambda = 0.016, chi-square =
29.107, p = 0.01) and area 24′ (Wilks’ lambda = 0.029, chi-
Table 2 Demographic features of patients with progressive
supranuclear palsy and healthy control subjects
Patients Control subjects p Value
n 16 14
Age at death, years 72.5 (6.92)a 75.7 (10.07) 0.34
Male sex, n (%) 9 (56) 9 (64) 0.8
Disease duration, years 8.2 (2.26)a – –
Postmortem delay, h, mean (SD) 6.29 (1.21) 7.53 (1.31) 0.01
aThree cases that underwent euthanasia were not included
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square = 24.737, p = 0.037). However, this result revealed by
the omnibus test could not be attributed to distinct recep-
tors in the subsequent post hoc tests, because none of them
reached significance in either brain structure. The signifi-
cant omnibus test in the case of the caudate nucleus can be
explained by the fact that 11 of 20 receptors presented
lower densities in cases with frontal presentation than in
those with nonfrontal presentation, and the opposite situ-
ation was found for only 8 receptors (5-HT2 receptor dens-
ities were identical in both groups). The significant
omnibus test in the case of area 24′ is due to the fact that
11 of 20 receptors presented higher densities in cases with
frontal presentation than in those with nonfrontal presenta-
tion, and the opposite situation was found for only 9 recep-
tors. However, relatively large SDs resulted for both regions
in a lack of significance at the post hoc test level.
Interestingly, discriminant analyses and subsequent post
hoc tests revealed that patients with PSP with and without
frontal presentation also had different variations from
control subjects in both the caudate nucleus (Fig. 1b) and
area 24′ (Fig. 1e). In the caudate nucleus (Fig. 1b), patients
with frontal presentation PSP (Wilks’ lambda = 0.009, chi-
square = 37.711, p = 0.002 by omnibus test) had signifi-
cantly higher pBZ and D1 but lower nACh and D2
receptor densities than did control subjects, whereas pa-
tients with nonfrontal PSP (Wilks’ lambda = 0.008, chi-
square = 43.257, p = 0.001 by omnibus test) presented sig-
nificantly lower nACh and higher A1 receptor densities
than did control subjects. In area 24′ (Fig. 1e), patients
with frontal PSP (Wilks’ lambda = 0.035, chi-square =
31.799, p = 0.033 by omnibus test) showed significantly
higher NMDA, GABAB, pBZ, 5-HT2, D1, and adenosine
receptor type 2A receptor densities than control subjects,
whereas patients with nonfrontal PSP (Wilks’ lambda =
0.005, chi-square = 58.876, p < 0.001 by omnibus test) pre-
sented higher GABAB and pBZ densities, but lower mus-
carinic cholinergic receptor type 1 (M1) densities, than
control subjects.
Mild versus moderate to severe tau burden
The degree of tau pathology in both area 24′ and the
caudate nucleus varied in our series of PSP brains. Tau
pathology in area 24′ was mild in seven brains. In five of
these cases, tau pathology in the caudate nucleus was also
mild, but in two of them, it was moderate to severe. Tau
pathology in area 24′ was moderate to severe in nine
brains. In four of these cases, tau pathology in the caudate
nucleus was also moderate to severe, but in five of them,
Table 3 Detailed clinical features of patients with progressive supranuclear palsy
Patient Age at
onset
(years)
Age at
death (years)
NINDS-SPSP
criteria during life
Frontal
presentation
Family
history
Relevant medication
in the last 3 months of life
Brain
weight (g)
Tau pathology
area 24'
Tau pathology
caudate
1a 71 73 Probable Nonfrontal Negative Clonazepam, temazepam,
piracetam
1398 Grade 3 Grade 2
2 66 76 Probable Frontal Negative Oxybutynin, acetylcysteine,
thiopental, pancuronium
1060 Grade 3 Grade 2
3 63 68 Probable Nonfrontal Positive Temazepam, oxybutynin 1405 Grade 3 Grade 4
4 70 79 Possible Frontal Positive Tolterodine 1069 Grade 2 Grade 2
5 51 60 Probable Frontal Negative Temazepam 1256 Grade 3 Grade 4
6a 74 80 Possible Nonfrontal Negative Thiopental, pancuronium 1100 Grade 2 Grade 1
7 66 75 Possible Frontal Negative Levomeprazine 1253 Grade 3 Grade 1
8 54 64 Possible Frontal Positive Amantadine 1290 Grade 3 Grade 1
9 79 85 Possible Nonfrontal Negative Oxazepam, nitrazepam,
acetylcysteine
1175 Grade 2 Grade 2
10 68 79 Probable Nonfrontal Negative Amitriptyline 922 Grade 2 Grade 1
11 60 72 Possible Nonfrontal Positive Levodopa/carbidopa,
amitriptyline
1045 Grade 2 Grade 2
12 60 67 Probable Frontal Positive Levodopa/carbidopa,
lormetazepam, nortriptyline
1013 Grade 4 Grade 2
13 62 70 Probable Nonfrontal Negative Amantadine, temazepam,
diazepam, amitriptyline
1160 Grade 2 Grade 3
14a 79 85 Possible Nonfrontal Negative Alprazolam, tamsulosin,
thiopental, pancuronium
1305 Grade 3 Grade 3
15 67 72 Possible Nonfrontal Positive Levodopa/carbidopa 1525 Grade 2 Grade 4
16 61 69 Probable Frontal Positive Midazolam, clozapine 1270 Grade 3 Grade 3
NINDS-SPSP National Institute of Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy
aPatients who underwent euthanasia by sodium thiopental and pancuronium bromide
Chiu et al. Alzheimer's Research & Therapy  (2017) 9:28 Page 6 of 13
it was only mild. Discriminant analyses of receptor dens-
ities resulted in a significant segregation of PSP cases into
patients with mild tau burden and patients with moderate
to severe tau burden in the caudate nucleus (Wilks’
lambda = 0.019, chi-square = 27.751, p = 0.015), but not in
area 24′ (Wilks’ lambda = 0.098, chi-square = 16.259, p =
0.298). Post hoc univariate F-tests revealed significantly
lower γ-aminobutyric acid type A-associated benzodiazep-
ine (BZ) binding site (p = 0.002) and 5-HT2 (p = 0.004) re-
ceptor densities in the caudate nucleus of PSP brains with
moderate to severe tau pathology than in PSP brains with
mild tau pathology.
Discriminant analyses and subsequent post hoc tests re-
vealed that PSP cases with no to mild and moderate to se-
vere tau pathology also compared differently from control
subjects in both the caudate nucleus (Fig. 1c) and area 24′
(Fig. 1f). In the caudate nucleus (Fig. 1c), patients with
PSP with no to mild tau pathology (Wilks’ lambda = 0.016,
chi-square = 39.477, p = 0.004 by omnibus test) presented
higher pBZ, D1, and A1 densities, but lower kainate
and nACh receptor densities, than did control subjects,
whereas patients with PSP with moderate to severe tau
pathology (Wilks’ lambda = 0.012, chi-square = 33.177, p
= 0.004 by omnibus test) showed higher A1 densities, but
lower benzodiazepine binding site as well as nACh, 5-
HT2, and D2 receptor densities, than control subjects.
In area 24′ (Fig. 1f ), patients with PSP with no to mild
tau pathology (Wilks’ lambda = 0.003, chi-square =
55.124, p < 0.001 by omnibus test) showed higher
GABAB, pBZ, and 5-HT2 receptor densities than did
control subjects, whereas patients with PSP with moder-
ate to severe tau pathology (Wilks’ lambda = 0.017, chi-
square = 44.973, p = 0.001 omnibus test) presented
higher NMDA, GABAB, pBZ, and serotonin receptor
type 1A densities than control subjects.
Discussion
The present study shows a divergence in the severity of
tau pathology between area 24′ and the caudate nucleus
of patients with PSP, as well as significant PSP-related
Table 4 Mean receptor densities in the caudate nucleus of control subjects and patients with progressive supranuclear palsy
Progressive supranuclear
palsy vs. control subjects
Progressive supranuclear palsy,
frontal vs. nonfrontal presentation
Progressive supranuclear palsy,
mild vs. severe tau pathology
Receptor Control subjects Patients p Value Frontal Nonfrontal p Value Mild Severe p Value
AMPA 607 (108) 583 (228) 0.749 477 (248) 665 (184) 0.102 631 (220) 503 (238) 0.290
Kainate 879 (61) 800 (73) 0.007 783 (70) 813 (76) 0.426 793 (68) 812 (85) 0.628
NMDA 1216 (42) 1218 (115) 0.951 1210 (122) 1224 (118) 0.823 1251 (116) 1163 (99) 0.413
mGlu2/3 9295 (625) 9416 (1455) 0.799 8735 (1746) 9945 (980) 0.100 9502 (1272) 9272 (1843) 0.771
GABAA 1273 (164) 1091 (203) 0.021 986 (214) 1173 (160) 0.065 1133 (178) 1021 (239) 0.304
GABAB 2477 (299) 2684 (397) 0.155 2529 (402) 2805 (370) 0.177 2788 (382) 2511 (389) 0.184
BZ 1684 (136) 1458 (330) 0.023 1463 (422) 1454 (266) 0.956 1635 (284) 1163 (121) 0.002
pBZ 1759 (89) 2050 (347) 0.005 2127 (392) 1989 (317) 0.450 2154 (365) 1876 (251) 0.123
M1 1174 (35) 922 (379) 0.018 968 (351) 886 (418) 0.686 904 (412) 952 (353) 0.815
M2 567 (56) 497 (127) 0.063 467 (140) 520 (119) 0.422 501 (158) 490 (54) 0.049
M3 1755 (36) 1740 (255) 0.829 1753 (309) 1731 (223) 0.869 1751 (299) 1723 (183) 0.843
nACh 200 (42) 105 (43) <0.001 97 (30) 111 (52) 0.522 119 (42) 82 (38) 0.094
α1 339 (28) 338 (53) 0.945 314 (51) 356 (50) 0.123 331 (47) 349 (65) 0.543
α2 467 (65) 510 (92) 0.199 502 (98) 516 (94) 0.767 498 (91) 531 (99) 0.500
5-HT1A 129 (16) 135 (27) 0.543 139 (28) 132 (28) 0.646 139 (33) 128 (12) 0.428
5-HT2 1069 (100) 976 (142) 0.074 976 (138) 976 (153) 0.996 1048 (105) 856 (115) 0.004
D1 291 (8) 332 (49) 0.010 341 (30) 326 (61) 0.456 349 (53) 305 (25) 0.085
D2 885 (50) 818 (103) 0.057 765 (108) 860 (82) 0.066 845 (99) 774 (102) 0.188
A1 1522 (239) 1952 (288) <0.001 1966 (327) 1942 (274) 0.786 1938 (349) 1977 (167) 0.806
A2A 1814 (195) 2105 (327) 0.014 2112 (409) 2100 (273) 0.944 2093 (391) 2124 (212) 0.863
Abbreviations: A1 Adenosine receptor type 1, A2A Adenosine receptor type 2A, α1 Adrenoceptor type 1, α2 Adrenoceptor type 2, AMPA α-Amino-3-hydroxy-5-me-
thyl-4-isoxazolepropionic acid, BZ γ-Aminobutyric acid type A-associated benzodiazepine-binding site, D1 Dopamine receptor type 1, D2 Dopamine receptor type
2, GABAA γ-Aminobutyric acid receptor type A, GABAB γ-Aminobutyric acid receptor type B, 5-HT1A Serotonin receptor type 1A, 5-HT2 Serotonin receptor type 2, M1,
M2, M3 Muscarinic cholinergic receptor types 1, 2, 3, mGlu2/3 Metabotropic glutamate receptor type 2/3, nACh Nicotinic cholinergic receptor of the α4/β2 type,
NMDA N-methyl-D-aspartate, pBZ Peripheral benzodiazepine receptor
Absolute densities (SD) in femtomoles per milligram of protein as well as p values for the post hoc tests (significant values are highlighted in boldface type) are
provided for each receptor type
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Fig. 1 (See legend on next page.)
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alterations in the densities of multiple receptors from
different neurotransmitter systems that differentially af-
fected both structures. In the caudate nucleus of PSP
brains, densities of pBZ and A1 receptors were higher,
and those of kainate and nACh receptors were lower,
than in control subjects. In area 24′, NMDA, GABAB,
pBZ, and 5-HT2 receptor densities were higher in PSP
than in control tissue. Furthermore, clinically relevant
PSP subgroups could be differentiated on the basis of
their receptor fingerprints.
To our knowledge, this is the first study to show that pa-
tients with PSP with frontal and nonfrontal presentations
(See figure on previous page.)
Fig. 1 Receptor fingerprints of progressive supranuclear palsy (PSP)-related receptor density alterations in the caudate nucleus (a–c) and area 24′ (d–f).
Polar plots showing the mean relative changes (in percent) in binding density of tissue obtained from the caudate nucleus (a) and area 24′ (d) of
patients with PSP (mean value coded by green lines, SD given by transparent surface) with respect to control subjects (0%, in black). Polar plots
showing the mean relative changes (in percent) in binding density of tissue obtained from the caudate nucleus (b) and area 24′ (e) of patients with
PSP with frontal presentation (mean value coded by red lines, SD given by red transparent surface) or with nonfrontal presentation (mean value coded
by blue lines, SD given by blue transparent surface) with respect to control subjects (0%, in black). Polar plots showing the mean relative changes (in
percent) in binding density of tissue obtained from the caudate nucleus (c) and area 24′ (f) of patients with PSP with no to mild tau pathology (mean
value coded by turquoise lines, SD given by turquoise transparent surface) or with moderate to severe tau pathology (mean value coded by pink lines,
SD given by pink transparent surface) with respect to control subjects (0%, in black). Colored asterisks highlight receptors that were significantly altered
in a given PSP cohort compared with control subjects. Hashtags indicate receptors significantly different when comparing PSP cases with no to mild
tau pathology and PSP cases with moderate to severe tau pathology. α4/β2 Nicotinic cholinergic receptors of the α4/β2 type, BZ γ-Aminobutyric acid
receptor type A-associated benzodiazepine binding sites, pBZ Peripheral benzodiazepine receptors
Table 5 Mean receptor densities in midcingulate area 24' of control subjects and progressive supranuclear palsy patients
Progressive supranuclear
palsy vs. control subjects
Progressive supranuclear
palsy, frontal vs. nonfrontal presentation
Progressive supranuclear palsy,
mild vs. severe tau pathology
Receptor Control subjects Patients p Value Frontal Nonfrontal p Value Mild Severe p Value
AMPA 731 (39) 739 (246) 0.899 681 (216) 785 (271) 0.421 695 (314) 773 (191) 0.546
Kainate 1129 (182) 1138 (150) 0.880 1102 (162) 1166 (144) 0.422 1161 (166) 1120 (145) 0.602
NMDA 1290 (102) 1455 (188) 0.007 1531 (155) 1397 (198) 0.164 1404 (272) 1495 (79) 0.350
mGlu2/3 7932 (1816) 8576 (1960) 0.361 8462 (1215) 8665 (2464) 0.845 8136 (2647) 8918 (1283) 0.448
GABAA 1975 (188) 2125 (241) 0.070 2078 (204) 2162 (272) 0.506 2232 (323) 2042 (112) 0.181
GABAB 4089 (484) 5126 (801) <0.001 4826 (360) 5360 (982) 0.176 5322 (1155) 4974 (376) 0.406
BZ 2686 (296) 3094 (1028) 0.164 2676 (525) 3419 (1226) 0.158 3567 (1373) 2726 (468) 0.165
pBZ 1698 (227) 2380 (416) <0.001 2444 (257) 2330 (402) 0.605 2452 (464) 2325 (394) 0.564
M1 621 (62) 505 (175) 0.023 581 (186) 446 (150) 0.131 458 (204) 542 (150) 0.358
M2 277 (43) 306 (43) 0.076 285 (29) 322 (47) 0.094 323 (54) 293 (29) 0.185
M3 1071 (84) 1135 (127) 0.117 1137 (142) 1133 (122) 0.959 1123 (129) 1144 (132) 0.752
nACh 116 (40) 102 (40) 0.325 104 (47) 100 (35) 0.833 111 (38) 94 (41) 0.425
α1 705 (57) 805 (174) 0.042 803 (204) 807 (159) 0.963 802 (195) 808 (167) 0.949
α2 1124 (190) 1288 (220) 0.039 1342 (201) 1246 (237) 0.407 1337 (221) 1250 (225) 0.453
5-HT1A 542 (53) 630 (119) 0.017 660 (99) 606 (133) 0.380 621 (172) 636 (65) 0.817
5-HT2 817 (74) 963 (170) 0.006 999 (192) 934 (158) 0.471 1001 (177) 933 (169) 0.446
D1 125 (22) 143 (25) 0.050 157 (17) 132 (26) 0.050 136 (29) 149 (21) 0.307
D2 71 (17) 92 (41) 0.092 75 (19) 104 (49) 0.165 107 (57) 80 (18) 0.191
A1 1300 (151) 1476 (318) 0.069 1542 (407) 1424 (241) 0.479 1413 (281) 1525 (352) 0.504
A2A 120 (9) 134 (30) 0.089 142 (24) 128 (35) 0.392 133 (38) 134 (26) 0.941
Abbreviations: A1 Adenosine receptor type 1, A2A Adenosine receptor type 2A, α1 Adrenoceptor type 1, α2 Adrenoceptor type 2, AMPA α-Amino-3-hydroxy-5-me-
thyl-4-isoxazolepropionic acid, BZ γ-Aminobutyric acid type A-associated benzodiazepine-binding site, D1 Dopamine receptor type 1, D2 Dopamine receptor type
2, GABAA γ-Aminobutyric acid receptor type A, GABAB γ-Aminobutyric acid receptor type B, 5-HT1A Serotonin receptor type 1A, 5-HT2 Serotonin receptor type 2, M1,
M2, M3 Muscarinic cholinergic receptor types 1, 2, 3, mGlu2/3 Metabotropic glutamate receptor type 2/3, nACh Nicotinic cholinergic receptor of the α4/β2 type,
NMDA N-methyl-D-aspartate, pBZ Peripheral benzodiazepine receptor
Absolute densities (SD) in femtomoles per milligram of protein as well as p values for the post hoc tests (significant values are highlighted in boldface type) are
provided for each receptor type. Note that although comparison of mild versus severe tau pathology resulted in a nonsignificant omnibus test, results of the post
hoc tests are displayed
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can be differentiated postmortem with a high degree of ac-
curacy on the basis of differences in receptor densities in
both the caudate nucleus and area 24′. Receptor finger-
prints also segregate mild from moderate to severe tau
cases. We are aware that a drawback of our study is the
fact that we were not able to assess the effect of medication
on receptor densities, owing to the variability in drug
therapy among patients.
Tau pathology is the histological hallmark of PSP,
though the severity and distribution of tau pathology may
differ between PSP subgroups [4]. The cerebral cortex and
caudate nucleus are among the regions where the differ-
ences in severity are greatest [4]. This divergence in sever-
ity of pathology between the cingulate cortex and the
caudate nucleus is supported by the present semiquantita-
tive evaluation and is reflected by our receptor data.
The widespread alterations in the GABAergic system
highlight its importance in the pathophysiology of PSP.
GABAB receptor densities were increased in area 24′ of
patients with PSP, but they were unaltered in the caudate
nucleus. Because the increased density of GABAB recep-
tors occurred in all PSP subgroups (frontal/nonfrontal
and mild/severe tau), they seem to be the most vulner-
able receptor type in PSP. Furthermore, the GABAB re-
ceptor increase in the midcingulate cortex is of
particular interest because its activation is associated
with the induction of long-term potentiation [22] and
results in amelioration of the cognitive impairment asso-
ciated with chronic cerebral hypoperfusion [23].
BZ binding sites were decreased in the caudate nucleus of
patients with PSP only in cases of moderate to severe tau
pathology. This decrease may be caused by a loss of
GABAergic projection neurons in this PSP subgroup, lead-
ing to a reduction of pre- and postsynaptic γ-aminobutyric
acid receptor type A (GABAA) and could explain the thera-
peutic effectivity of BZ agonists [24]. The GABAA receptor
density demonstrated by the binding with the agonist
[3H]muscimol also showed a decrease, but this did not reach
significance (Tables 4 and 5). Because the agonistic binding
prefers high-affinity binding sites of the receptor, these data
may indicate a shift of the ratio between low- and high-
affinity binding sites of the GABAA receptor in PSP.
Densities of pBZ receptors were higher in area 24′ and
the caudate nucleus of patients with PSP than in control
subjects. This is in line with the increased PK11195
binding in these regions revealed by a positron emission
tomography (PET) study [25] and reflects microglial ac-
tivation. However, when the cohort was subdivided into
frontal/nonfrontal cases or mild/severe tau pathology,
consistent alterations were found only in area 24′. Taken
together, receptors of the GABAergic system are more
affected in area 24′ than in the caudate nucleus, and im-
pairment does not depend on the severity of tau path-
ology and frontal or nonfrontal clinical type.
Our findings of widespread PSP-related changes in the
glutamatergic system may be relevant for potential future
treatment strategies in PSP, similar to recent studies in
Parkinson’s disease [26, 27]. The divergence in the severity
of receptor impairments between cortical and subcortical
sites is further supported by our findings regarding
NMDA receptors, which were altered only in area 24′.
This increase in NMDA receptor densities is probably due
to region-specific disease-induced alterations, and not
caused by the long-term administration of amantadine,
because patients treated with this NMDA receptor antag-
onist (patients 8 and 12; see Table 3) presented normal
NMDA receptor densities. The unchanged NMDA recep-
tor density in the caudate nucleus is in accordance with
the one other study investigating NMDA receptors in pa-
tients with PSP [28]. Furthermore, we found a decrease of
kainate receptor densities but unaltered α-amino-3-hy-
droxy-5-methyl-4-isoxazolepropionic acid and metabotro-
pic glutamate receptor type 2/3 densities, where up to
now no information was available in patients with PSP.
Drugs targeting the cholinergic system have failed to re-
lieve the cognitive and motor impairments of PSP [29].
Interestingly, of the four cholinergic receptor types exam-
ined here, only the nACh receptors were found to be al-
tered in the PSP cohort (as a whole and in all subgroups),
though only in the caudate nucleus. Our results for nACh
and M1 receptors in the caudate nucleus are in line with
previous findings [11]. The unaltered caudate nucleus
muscarinic cholinergic receptor type 2 (M2) receptor
densities, however, contrast with the findings in another
postmortem study in which researchers reported reduced
M2 receptor densities in the posterior caudate nucleus
[12]. The discrepancy may be explained by differences in
postmortem delay times (45 h versus 6 h in our study); li-
gands used (the antagonist [3H]-AFDX 384 versus the
agonist [3H]oxotremorine-M in our study); or the rostro-
caudal anatomical, neurochemical, and functional differ-
ences that characterize the caudate nucleus [30].
Interestingly, the nACh receptor plays a major role in
the control of dopamine release in the caudate nucleus
[31]. Consequently, the remarkably strong decrease in
nACh receptor densities leads to a reduction of dopamine
release, which results in a global impairment of dopamin-
ergic effects in the caudate nucleus of patients with PSP.
The normal density of adrenoceptors in the caudate
nucleus and area 24′ in our cases, together with the nor-
mal adrenaline levels in various brain regions of patients
with PSP as found by Kish et al. [32], as well as the inef-
fectiveness of noradrenergic replacement therapies [33],
suggests that this neurotransmitter system does not con-
tribute significantly to the symptomatology of PSP. It
must be noted, however, that researchers in the single
other autoradiographic study on adrenoceptors in PSP
to date found a generalized reduction of adrenoceptor
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type 2 receptors [34], though their findings were based
on a case report.
The 5-HT2 receptor also emphasizes the divergent se-
verity of alterations between area 24′ and the caudate nu-
cleus in PSP, because it was increased only in the former
structure, preferentially in the frontal group. Our results
are difficult to compare with those of an in vivo PET im-
aging study in which investigators reported normal dens-
ities of 5-HT2 receptors in the neocortex, but higher
concentrations in the putamen [35], because different re-
gions were examined and different ligands ([18F]altanserin
versus [3H]ketanserin in our cases) were used. Further-
more, [18F]altanserin PET does not directly reflect 5-HT2
receptor density, because it is confounded by the uptake
of blood-brain barrier-penetrating metabolites and non-
specific binding of [18F]altanserin itself [36].
The decrease of 5-HT2 receptor densities in the caud-
ate nucleus of PSP brains with moderate to severe tau
pathology compared with those with mild tau pathology
cannot be explained merely by a more severe neurode-
generation in the former group, because we did not ob-
serve an association between tau pathology and 5-HT2
receptor alterations in area 24′. Interestingly, although a
differential effect of serotonergic denervation on tau
pathology in various brain regions has been described
previously, the underlying explanation for this selective
vulnerability remains unclear [37].
Dopaminergic receptors are localized on medium
spiny stellate cells. Cells expressing D1 receptors, or D1
colocalized with D2 receptors, preferentially project to
the substantia nigra and the internal segment of the
globus pallidus, whereas those expressing D2 receptors
target the external segment of the globus pallidus [38].
Our finding of unaltered D1 receptor densities is in
accordance with previous reports [10, 39], and the
unchanged D2 receptor densities described here add to
the controversial data concerning this receptor type
[10, 11, 39].
A1 receptors are frequently localized presynaptically
and control glutamate release. Thus, the significant PSP-
related increase of receptor densities in the caudate nu-
cleus may be a plastic reaction to (1) decreased inhib-
ition resulting from BZ binding site downregulation and
(2) increased excitation resulting from higher NMDA
and lower kainate receptor densities, because the latter
can also control glutamate release. The PSP-related in-
crease in A1 receptor densities in the caudate nucleus
may be the result of an ongoing inflammatory process
because these receptors are expressed in microglia [40].
Furthermore, it could be a compensatory mechanism to
counteract the decreased concentrations of the adeno-
sine precursors adenosine diphosphate and adenosine
triphosphate measured in the basal ganglia of patients
with PSP [41]. Therefore, an intriguing question is
whether modulation targeting the adenosine receptors
may represent a therapeutic strategy in PSP.
Conclusions
We have demonstrated the involvement of multiple non-
dopaminergic neurotransmitter systems in the patho-
physiology of PSP, which may be relevant for potential
novel treatment strategies. We provide further evidence
that the midcingulate cortex may prove to be a key re-
gion in this disease. GABAergic, glutamatergic, and sero-
tonergic receptors in patients with PSP deviated most
from those of control subjects in area 24′, where the
highest frequency of tau pathology was found. This is in
sharp contrast to dopaminergic, cholinergic, and adeno-
sine receptors, which were preferentially impaired in the
caudate nucleus. Finally, “receptor fingerprints” not only
differentiated patients with PSP from control subjects
neurochemically but also segregated PSP subgroups
when clinical parameters such as presence of frontal
presentation and severity of tau pathology were taken
into consideration.
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